InvestSMART

Invion Limited (ASX:IVX)

ALERT: Price-sensitive ASX Announcement for IVX
Current share price for IVX : $0.041 -0.02 (-32.79%)+
Announcement
Release
21 Apr 2026 9:46AM
Price at Release
$0.061
Full Release
download
Summary
Invion Limited has announced the expansion of its Non-Melanoma Skin Cancer (NMSC) trial to include Basal Cell Carcinoma (BCC) patients after receiving positive safety and efficacy signals from a cohort of squamous cell carcinoma (SCC) patients. The Safety Review Committee (SRC) approved this expansion following consistent favorable safety profiles and efficacy signals, including lesion size reductions and complete resolution in some cases. BCC represents the most prevalent form of skin cancer, accounting for 80% of cases, which opens new market pathways due to the inability to grow BCCs in animal models. This expansion marks a significant milestone for INV043, positioning Invion to further develop human BCC data to support its Phase II strategy. The trial also aligns with Invion's upcoming anogenital trial, which will utilize the same topical formulation of INV043.
Key Points
  • Expansion into Basal Cell Carcinoma (BCC) patients in the NMSC trial.
  • Approval from the Safety Review Committee (SRC) based on SCC results.
  • Strong safety data with no adverse effects observed.
  • Reduction in lesion size and complete resolution in some cases.
  • BCC accounts for 80% of all skin cancers.
  • Significant milestone for INV043 and future Phase II strategy.
  • Upcoming anogenital trial to use the same formulation of INV043.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.